Would you consider the use of ctDNA as part of surveillance in high risk TNBC patients?

Patients with significant residual TNBC following NAC have an increased risk of recurrence and death within 3 years, despite SOC adjuvant capecitabine (EA1131). The presence of ctDNA following initial active treatment (using Signatera or other platforms) has reliably shown to predict risk of recurre...

I would not recommend unless part of a clinical trial as we do not know what to do with the information. We all recall how randomized trials using tumor markers and surveillance scans did not impact outcome, unclear how this is truly different.